Pharminent

Labor Department finalizes PBM fee disclosure rule for employers

The Labor Department finalized a rule requiring pharmacy benefit managers to share a broad swath of fee and compensation data with self-funded employer clients starting in 2027. Employers welcomed the rule, while PBMs called it government overreach.

HHS policy allows compounding of six unapproved wellness peptides

Health Secretary Robert F. Kennedy Jr. backed a new policy allowing licensed professionals to use six wellness-focused peptides that are not approved by the FDA in compounded medicines.

EMA’s PRAC starts review of Deanxit at October meeting

The EMA’s Pharmacovigilance Risk Assessment Committee began a review of Deanxit, a fixed-dose combination of flupentixol and melitracen used for depression and anxiety, at its meeting held October 26-29, 2026. Ongoing referrals include flupentixol/melitracen-containing medicines and parenteral iron-containing medicines.

Genmab’s cancer antibody succeeds in phase 3 head and neck trial

Genmab said a recently acquired antibody succeeded in a phase 3 trial in a form of head and neck cancer, with findings suggesting it could become a new treatment standard. The company’s market value rose by more than $7 billion.

BioMarin licenses long-acting Fabry enzyme therapy for $70M upfront

BioMarin paid $70 million upfront for rights to a clinical-stage, long-acting subcutaneous enzyme replacement therapy for Fabry disease developed by Hanmi and GC Biopharma.

Ferring to acquire fertility biotech Gameto in $1.38B deal

Ferring agreed to acquire fertility biotech Gameto in a deal worth up to $1.38 billion.

Sanofi’s CEO says M&A and licensing critical before Dupixent patent loss

Sanofi’s CEO said adding to the company’s pipeline through M&A and licensing will be “critical” as it prepares for generic competition to Dupixent.

Lilly’s Mounjaro and Zepbound top $16B in third quarter

Third-quarter sales of Lilly’s tirzepatide products Mounjaro and Zepbound topped $16 billion, exceeding total revenue for many large pharmaceutical companies.

Dren Bio raises $350M for dibotatug late-stage development

Dren Bio closed an oversubscribed $350 million private financing round to advance its lead investigational therapy dibotatug through late-stage clinical evaluation, regulatory submission and potential commercialization. The company said the funds will support pivotal trials of the possible first-in-class therapy for rare blood cancers.

Aspen Neuroscience raises $140M in Nasdaq IPO

Aspen Neuroscience, a San Diego biotechnology startup developing a cell therapy for Parkinson’s disease, raised $140 million in its IPO.

Bambusa closes Nasdaq IPO as Corxel pursues SPAC merger

Bambusa Therapeutics completed its Nasdaq IPO, while Corxel is pursuing a public debut through a merger with a blank-check company.